ArticleLeukemia2020
Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance.
Abstract readLetter
In one paragraph
Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6.Blood cancer journal · 2022Pooled it
- ULK4 and CDKN2A polymorphisms influence the risk of developing monoclonal gammopathy of undetermined significance.International journal of cancer · 2026Article
- Clonal Hematopoietic Mutations in Plasma Cell Disorders: Clinical Subgroups and Shared Pathogenesis.Genomics, proteomics & bioinformatics · 2025Article
- Haplotype analysis identifies functional elements in monoclonal gammopathy of unknown significance.Blood cancer journal · 2024Article
- It is worth the weight: obesity and the transition from monoclonal gammopathy of undetermined significance to multiple myeloma.Blood advances · 2023Review
- Epidemiology, genetics and treatment of multiple myeloma and precursor diseases.International journal of cancer · 2021Review
- Search for AL amyloidosis risk factors using Mendelian randomization.Blood advances · 2021Article
- Review
- Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.Blood cancer journal · 2021Article
- Obesity as a Possible Risk Factor for Progression from Monoclonal Gammopathy of Undetermined Significance Progression into Multiple Myeloma: Could Myeloma Be Prevented with Metformin Treatment?Advances in hematology · 2021Review
- Host immune genetic variations influence the risk of developing acute myeloid leukaemia: results from the NuCLEAR consortium.Blood cancer journal · 2020Article
- Search for multiple myeloma risk factors using Mendelian randomization.Blood advances · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Subhayan ChattopadhyayDivision of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-8599-2971
Hauke ThomsenDivision of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-5951-3116
Niels WeinholdDepartment of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Iman MezianeDivision of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany.
Stefanie HuhnDepartment of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Miguel Inacio da Silva FilhoDivision of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany.
Pavel VodickaInstitute of Experimental Medicine, Academy of Sciences of the Czech Republic, Videnska 1083, 142 00, Prague, Czech Republic.
Ludmila VodickovaInstitute of Experimental Medicine, Academy of Sciences of the Czech Republic, Videnska 1083, 142 00, Prague, Czech Republic.
Per HoffmannInstitute of Human Genetics, University of Bonn, Bonn, Germany.
Markus M NöthenInstitute of Human Genetics, University of Bonn, Bonn, Germany.
Karl-Heinz JöckelInstitute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Börge SchmidtInstitute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Stefano LandiDepartment of Biology, University of Pisa, Pisa, Italy.
Roman HajekDepartment of Hematooncology, University Hospital Ostrava, 17. listopadu 1790, 708 52, Ostrava, Czech Republic.
Göran HallmansDepartment of Medical Biosciences/Pathology, University of Umea, Umea, Sweden.
Ulrika Pettersson-KymmerClinical Pharmacology, Department of Pharmacology and Clinical Neuroscience, Umea University, Umea, Sweden.
Claes OhlssonCentre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Paolo MilaniAmyloidosis Research and Treatment Center, Foundation "Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo" and Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Giampaolo MerliniAmyloidosis Research and Treatment Center, Foundation "Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo" and Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Dorota RowcienoNational Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, Rowland Hill Street, London, NW32PF, UK.
Philip HawkinsNational Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, Rowland Hill Street, London, NW32PF, UK.
Ute HegenbartDepartment of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-1917-6746
Giovanni PalladiniAmyloidosis Research and Treatment Center, Foundation "Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo" and Department of Molecular Medicine, University of Pavia, Pavia, Italy.ORCID http://orcid.org/0000-0001-5994-5138
Ashutosh WechalekarNational Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, Rowland Hill Street, London, NW32PF, UK.
Stefan O SchönlandDepartment of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Richard HoulstonDivision of Genetics and Epidemiology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.ORCID http://orcid.org/0000-0002-5268-0242
Hartmut GoldschmidtDepartment of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Kari HemminkiDivision of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany.
Asta FörstiDivision of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany. a.foersti@kitz-heidelberg.de.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Genetic LociPolymorphism, Single NucleotideBiomarkers, TumorCohort StudiesGenome-Wide Association StudyHumansImmunoglobulin Light-chain AmyloidosisMonoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaPrognosisBiomarkers, Tumor
Identifiers
PMID
31695157What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.